
‘Exciting to report’: Dapirolizumab bests placebo in achieving lupus low disease activity
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Dapirolizumab pegol, a novel CD40L inhibitor, is superior to …